Louis Licamele

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

Steven W. Lockley, Marlene Dressman, Louis Licamele et al. · The Lancet · 2015 · 292 citations

Sleep Medicine, Sleep Health, Sleep +13

Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia

Simona Volpi, Steven G. Potkin, Anil K. Malhotra et al. · The Journal of Clinical Psychiatry · 2009 · 205 citations

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

Christian Lavedan, Louis Licamele, Simona Volpi et al. · Molecular Psychiatry · 2008 · 150 citations

Genome-wide Association Study, Antipsychotic Iloperidone, Psychiatry +9

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

Simona Volpi, Callie Heaton, Kendra Mack et al. · Molecular Psychiatry · 2008 · 104 citations · Full text

Psychiatry, Psychotropic Medication, Genetics +8

Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia

Mihael H. Polymeropoulos, Louis Licamele, Simona Volpi et al. · Schizophrenia Research · 2009 · 83 citations

Psychiatry, Fatty Acids, Medicine +9